Rapid response of locally advanced oral squamous cell carcinoma to apatinib: A case report

There are no effective therapeutic options for locally advanced head and neck squamous cell carcinoma (HNSCC). Additionally, there is no standard therapy for patients subjected to multiple lines of treatment. Angiogenesis plays a key role in tumor growth and metastasis. Therefore, inhibition of tumo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	He Jian, Zhang Yangyang, Gao Jin, Qian Liting
Formato:	article
Lenguaje:	EN
Publicado:	De Gruyter 2021
Materias:	apatinib oral cancer head and neck squamous cell carcinoma vegfr-2 Medicine R
Acceso en línea:	https://doaj.org/article/a2e96ccf0924411f9ffcf5462331a89e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a2e96ccf0924411f9ffcf5462331a89e
record_format	dspace
spelling	oai:doaj.org-article:a2e96ccf0924411f9ffcf5462331a89e2021-12-05T14:10:55ZRapid response of locally advanced oral squamous cell carcinoma to apatinib: A case report2391-546310.1515/med-2021-0360https://doaj.org/article/a2e96ccf0924411f9ffcf5462331a89e2021-11-01T00:00:00Zhttps://doi.org/10.1515/med-2021-0360https://doaj.org/toc/2391-5463There are no effective therapeutic options for locally advanced head and neck squamous cell carcinoma (HNSCC). Additionally, there is no standard therapy for patients subjected to multiple lines of treatment. Angiogenesis plays a key role in tumor growth and metastasis. Therefore, inhibition of tumor angiogenesis is an important strategy for tumor therapy. Apatinib is a novel tyrosine kinase inhibitor that inhibits angiogenesis by targeting vascular endothelial growth factor receptor-2 (VEGFR-2). The effect of apatinib on HNSCC has not been clearly established. In this study, we administered apatinib in combination with anti-epidermal growth factor receptor (EGFR) targeted and systemic chemotherapy for the treatment of oral cancer and to achieve better disease outcomes. To avoid fatal bleeding, after achieving good clinical outcomes, the follow-up treatment plan was adjusted. The efficacy of apatinib combined with anti-EGFR targeted and systemic chemotherapy for the treatment of oral cancer has not been previously reported. Our findings show the therapeutic potential of apatinib for advanced HNSCC patients with multiple lines of chemotherapy, especially for patients with large neck masses.He JianZhang YangyangGao JinQian LitingDe Gruyterarticleapatiniboral cancerhead and neck squamous cell carcinomavegfr-2MedicineRENOpen Medicine, Vol 16, Iss 1, Pp 1668-1672 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	apatinib oral cancer head and neck squamous cell carcinoma vegfr-2 Medicine R
spellingShingle	apatinib oral cancer head and neck squamous cell carcinoma vegfr-2 Medicine R He Jian Zhang Yangyang Gao Jin Qian Liting Rapid response of locally advanced oral squamous cell carcinoma to apatinib: A case report
description	There are no effective therapeutic options for locally advanced head and neck squamous cell carcinoma (HNSCC). Additionally, there is no standard therapy for patients subjected to multiple lines of treatment. Angiogenesis plays a key role in tumor growth and metastasis. Therefore, inhibition of tumor angiogenesis is an important strategy for tumor therapy. Apatinib is a novel tyrosine kinase inhibitor that inhibits angiogenesis by targeting vascular endothelial growth factor receptor-2 (VEGFR-2). The effect of apatinib on HNSCC has not been clearly established. In this study, we administered apatinib in combination with anti-epidermal growth factor receptor (EGFR) targeted and systemic chemotherapy for the treatment of oral cancer and to achieve better disease outcomes. To avoid fatal bleeding, after achieving good clinical outcomes, the follow-up treatment plan was adjusted. The efficacy of apatinib combined with anti-EGFR targeted and systemic chemotherapy for the treatment of oral cancer has not been previously reported. Our findings show the therapeutic potential of apatinib for advanced HNSCC patients with multiple lines of chemotherapy, especially for patients with large neck masses.
format	article
author	He Jian Zhang Yangyang Gao Jin Qian Liting
author_facet	He Jian Zhang Yangyang Gao Jin Qian Liting
author_sort	He Jian
title	Rapid response of locally advanced oral squamous cell carcinoma to apatinib: A case report
title_short	Rapid response of locally advanced oral squamous cell carcinoma to apatinib: A case report
title_full	Rapid response of locally advanced oral squamous cell carcinoma to apatinib: A case report
title_fullStr	Rapid response of locally advanced oral squamous cell carcinoma to apatinib: A case report
title_full_unstemmed	Rapid response of locally advanced oral squamous cell carcinoma to apatinib: A case report
title_sort	rapid response of locally advanced oral squamous cell carcinoma to apatinib: a case report
publisher	De Gruyter
publishDate	2021
url	https://doaj.org/article/a2e96ccf0924411f9ffcf5462331a89e
work_keys_str_mv	AT hejian rapidresponseoflocallyadvancedoralsquamouscellcarcinomatoapatinibacasereport AT zhangyangyang rapidresponseoflocallyadvancedoralsquamouscellcarcinomatoapatinibacasereport AT gaojin rapidresponseoflocallyadvancedoralsquamouscellcarcinomatoapatinibacasereport AT qianliting rapidresponseoflocallyadvancedoralsquamouscellcarcinomatoapatinibacasereport
_version_	1718371620388601856

Rapid response of locally advanced oral squamous cell carcinoma to apatinib: A case report

Ejemplares similares